Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection

Autores
Artman, Chad; Idegwu, Nnebuefe; Brumfield, Kyle D.; Lai, Ken; Hauta, Shirley; Falzarano, Darryl; Parreño, Gladys Viviana; Yuan, Lijuan; Geyer, James D.; Goepp, Julius G.
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.
Instituto de Virología
Fil: Artman, Chad. Scaled Microbiomics; Estados Unidos
Fil: Idegwu, Nnebuefe. Scaled Microbiomics; Estados Unidos
Fil: Brumfield, Kyle D. College Park Campus. University of Maryland. Maryland Pathogen Research Institute; Estados Unidos
Fil: Brumfield, Kyle D. College Park Campus. University of Maryland. University of Maryland Institute for Advanced Computer Studies; Estados Unidos
Fil: Lai, Ken. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá
Fil: Hauta, Shirley. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá
Fil: Falzarano, Darryl. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá
Fil: Falzarano, Darryl. University of Saskatchewan. Western College of Veterinary Medicine. Department of Veterinary Microbiology; Canadá
Fil: Parreño, Gladys Viviana. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria (INTA). INCUINTA. Instituto de Virologia e Innovaciones Tecnologicas (IVIT); Argentina
Fil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Geyer, James D. University of Alabama. College of Community Health Science. Institute for Rural Health Research; Estados Unidos
Fil: Goepp, Julius G. Scaled Microbiomics; Estados Unidos
Fuente
Viruses 14 (11) : 2371 (2022)
Materia
Norovirus
Caliciviridae
Foodborne Disease
Gastroenteritis
Enfermedades Transmitidas por Alimentos
Polyclonal Avian Immunoglobulins
Human Norovirus Infection
Prophylaxis
Outbreak Prevention and Control
Inmunoglobulinas Aviares Policlonales
Infección por Norovirus Humano
Profilaxis
Prevención y Control de Brotes
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/16367
Acceder
id INTADig_c313f16d89aaf6f385c7b8a74ed86add
oai_identifier_str oai:localhost:20.500.12123/16367
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infectionArtman, ChadIdegwu, NnebuefeBrumfield, Kyle D.Lai, KenHauta, ShirleyFalzarano, DarrylParreño, Gladys VivianaYuan, LijuanGeyer, James D.Goepp, Julius G.NorovirusCaliciviridaeFoodborne DiseaseGastroenteritisEnfermedades Transmitidas por AlimentosPolyclonal Avian ImmunoglobulinsHuman Norovirus InfectionProphylaxisOutbreak Prevention and ControlInmunoglobulinas Aviares PoliclonalesInfección por Norovirus HumanoProfilaxisPrevención y Control de BrotesBackground: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.Instituto de VirologíaFil: Artman, Chad. Scaled Microbiomics; Estados UnidosFil: Idegwu, Nnebuefe. Scaled Microbiomics; Estados UnidosFil: Brumfield, Kyle D. College Park Campus. University of Maryland. Maryland Pathogen Research Institute; Estados UnidosFil: Brumfield, Kyle D. College Park Campus. University of Maryland. University of Maryland Institute for Advanced Computer Studies; Estados UnidosFil: Lai, Ken. University of Saskatchewan. Vaccine and Infectious Disease Organization; CanadáFil: Hauta, Shirley. University of Saskatchewan. Vaccine and Infectious Disease Organization; CanadáFil: Falzarano, Darryl. University of Saskatchewan. Vaccine and Infectious Disease Organization; CanadáFil: Falzarano, Darryl. University of Saskatchewan. Western College of Veterinary Medicine. Department of Veterinary Microbiology; CanadáFil: Parreño, Gladys Viviana. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria (INTA). INCUINTA. Instituto de Virologia e Innovaciones Tecnologicas (IVIT); ArgentinaFil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Geyer, James D. University of Alabama. College of Community Health Science. Institute for Rural Health Research; Estados UnidosFil: Goepp, Julius G. Scaled Microbiomics; Estados UnidosMDPI2023-12-27T14:29:53Z2023-12-27T14:29:53Z2022-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/16367https://www.mdpi.com/1999-4915/14/11/23711999-4915https://doi.org/10.3390/v14112371Viruses 14 (11) : 2371 (2022)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-29T13:46:17Zoai:localhost:20.500.12123/16367instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-29 13:46:17.598INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
title Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
spellingShingle Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
Artman, Chad
Norovirus
Caliciviridae
Foodborne Disease
Gastroenteritis
Enfermedades Transmitidas por Alimentos
Polyclonal Avian Immunoglobulins
Human Norovirus Infection
Prophylaxis
Outbreak Prevention and Control
Inmunoglobulinas Aviares Policlonales
Infección por Norovirus Humano
Profilaxis
Prevención y Control de Brotes
title_short Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
title_full Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
title_fullStr Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
title_full_unstemmed Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
title_sort Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection
dc.creator.none.fl_str_mv Artman, Chad
Idegwu, Nnebuefe
Brumfield, Kyle D.
Lai, Ken
Hauta, Shirley
Falzarano, Darryl
Parreño, Gladys Viviana
Yuan, Lijuan
Geyer, James D.
Goepp, Julius G.
author Artman, Chad
author_facet Artman, Chad
Idegwu, Nnebuefe
Brumfield, Kyle D.
Lai, Ken
Hauta, Shirley
Falzarano, Darryl
Parreño, Gladys Viviana
Yuan, Lijuan
Geyer, James D.
Goepp, Julius G.
author_role author
author2 Idegwu, Nnebuefe
Brumfield, Kyle D.
Lai, Ken
Hauta, Shirley
Falzarano, Darryl
Parreño, Gladys Viviana
Yuan, Lijuan
Geyer, James D.
Goepp, Julius G.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Norovirus
Caliciviridae
Foodborne Disease
Gastroenteritis
Enfermedades Transmitidas por Alimentos
Polyclonal Avian Immunoglobulins
Human Norovirus Infection
Prophylaxis
Outbreak Prevention and Control
Inmunoglobulinas Aviares Policlonales
Infección por Norovirus Humano
Profilaxis
Prevención y Control de Brotes
topic Norovirus
Caliciviridae
Foodborne Disease
Gastroenteritis
Enfermedades Transmitidas por Alimentos
Polyclonal Avian Immunoglobulins
Human Norovirus Infection
Prophylaxis
Outbreak Prevention and Control
Inmunoglobulinas Aviares Policlonales
Infección por Norovirus Humano
Profilaxis
Prevención y Control de Brotes
dc.description.none.fl_txt_mv Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.
Instituto de Virología
Fil: Artman, Chad. Scaled Microbiomics; Estados Unidos
Fil: Idegwu, Nnebuefe. Scaled Microbiomics; Estados Unidos
Fil: Brumfield, Kyle D. College Park Campus. University of Maryland. Maryland Pathogen Research Institute; Estados Unidos
Fil: Brumfield, Kyle D. College Park Campus. University of Maryland. University of Maryland Institute for Advanced Computer Studies; Estados Unidos
Fil: Lai, Ken. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá
Fil: Hauta, Shirley. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá
Fil: Falzarano, Darryl. University of Saskatchewan. Vaccine and Infectious Disease Organization; Canadá
Fil: Falzarano, Darryl. University of Saskatchewan. Western College of Veterinary Medicine. Department of Veterinary Microbiology; Canadá
Fil: Parreño, Gladys Viviana. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria (INTA). INCUINTA. Instituto de Virologia e Innovaciones Tecnologicas (IVIT); Argentina
Fil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Geyer, James D. University of Alabama. College of Community Health Science. Institute for Rural Health Research; Estados Unidos
Fil: Goepp, Julius G. Scaled Microbiomics; Estados Unidos
description Background: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:221 (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (p < 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (p < 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.
publishDate 2022
dc.date.none.fl_str_mv 2022-11
2023-12-27T14:29:53Z
2023-12-27T14:29:53Z
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/16367
https://www.mdpi.com/1999-4915/14/11/2371
1999-4915
https://doi.org/10.3390/v14112371
url http://hdl.handle.net/20.500.12123/16367
https://www.mdpi.com/1999-4915/14/11/2371
https://doi.org/10.3390/v14112371
identifier_str_mv 1999-4915
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Viruses 14 (11) : 2371 (2022)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1844619183328854016
score 12.749369

Publicaciones similares